Eberhard Krausz
Group Leader, Evotec (France) SAS
Eberhard Krausz is listed as Group Leader, Evotec (France) SAS. Eberhard is scheduled to speak at SLAS 2027 International Conference & Exhibition on 31 January 2027.
Compiled from published conference agendas; not yet confirmed by Eberhard. Is this you? Claim this profile.
About
Dr. Eberhard Krausz has been a group leader in target validation and early drug discovery (oncology) for Evotec (France) for 8 years. Before, he co-founded VIB Discovery Sciences, has supported scientists and teams during various positions in industry (Tibotec, J&J/Janssen) and academia. He specialises in technology selection, target identification & validation, the development of physiologically relevant cell-based assays, screening and drug discovery. In 2003-2008, he led the central high-content screening labs at the Max Planck Institute in Dresden, Germany and before that held responsible positions in biotech industry at Cenix BioScience (Germany) and Cyclacel (Scotland, UK) dealing with RNA interference and drug discovery. Eberhard is a SLAS Fellow member since 2022 and has been serving several committees and councils at SLAS.
Upcoming
SLAS 2027 International Conference & Exhibition 30 January 2027 – 3 February 2027
- High Content Screening: An Introduction to Instrumentation, Assay Development, Screening, Image and Data Analysis Speaker · 31 January 2027
- 3D Patient-Derived Cancer Models for Target Validation and Drug Discovery Speaker · 2 February 2027
Spoke alongside
People who have shared a session with Eberhard at events on B2DB.
- Tilen Kranjc CEO · TK Analytics 1 shared session